Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.47 |
| ▸ | SRC | P12931 | 1/20 | 0.34 |
| ▸ | TYR | P14679 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | DRD1 | P21728 | 3/20 | 0.32 |
| ▸ | TUBB1 | Q9H4B7 | 3/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12493025 | 0.86 | ALDH1A1 (0.43) | ALDH1A3ALDH1A1TUBB1MAPTTSHR | |
| SCHEMBL16057085 | 0.82 | DRD1 (0.44) | ALDH1A3SRCALDH1A1SMN1; SMN2DRD1 | |
| SCHEMBL7842559 | 0.78 | ALDH1A3 (0.48) | ALDH1A3SRCTYRALDH1A1CYP1A2 | |
| SCHEMBL2006167 | 0.78 | SRC (0.52) | ALDH1A3SRCTYRALDH1A1CYP1A2 | |
| SCHEMBL2306018 | 0.77 | TUBB1 (0.47) | SRCALDH1A1TUBB1TSHR | |
| SCHEMBL8996034 | 0.77 | ALOX5 (0.49) | ALDH1A3ALDH1A1TSHR | |
| SCHEMBL11916153 | 0.76 | RAPGEF4 (0.30) | — | |
| SCHEMBL2675310 | 0.76 | SRC (0.32) | ALDH1A3SRCTYRALDH1A1SMN1; SMN2 | |
| SCHEMBL14033967 | 0.76 | ALDH1A3 (0.52) | ALDH1A3TYRALDH1A1SMN1; SMN2DRD1 | |
| SCHEMBL7842122 | 0.74 | ALDH1A1 (0.50) | ALDH1A3ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1756112-B1 | PYRROLOBENZIMIDAZOLONES AND THEIR USE AS ANTIPROLIFERATIVE AGENTS | BOEHRINGER INGELHEIM INT (DE) | 2011-10-26 | — | — | EP | disclosed |
| US-7714010-B2 | Pyrrolobenzimidazolones and their use as anti-proliferative agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-05-11 | — | — | US | disclosed |
| EP-1756112-A1 | PYRROLOBENZIMIDAZOLONES AND THEIR USE AS ANTIPROLIFERATIVE AGENTS | Boehringer Ingelheim International GmbH (DE) | 2007-02-28 | — | — | EP | disclosed |
| US-20050261350-A1 | Pyrrolobenzimidazolones and their use as anti-proliferative agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-24 | — | — | US | disclosed |
| WO-2005111040-A1 | PYRROLOBENZIMIDAZOLONES AND THEIR USE AS ANTIPROLIFERATIVE AGENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261350-A1 | Pyrrolobenzimidazolones and their use as anti-proliferative agents | MKI67, CCNI, CCNA1 | ALDH1A3 2645/4885SRC 594/4885TYR 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.